Consider the (biological/chemica/medical/financial ) impact of WW AD trial results being reported at one time , assuming the results presented are as expected and as earned by AVXL WW Team.
As you see WW results, think about the powerful message AVXL can deliver regarding our MOA and the overall efficacy of S1r promise to all the CNS (AD and other) disease sufferers WW. IMO, when the work done by AVXL and the clinical team sinks in people will see what we have. ("When you see what we have, you will understand why we did it this way" or similar Dr.M. quote) FDA are alligned WW by nationalized regulatory body agreement (s) w/these countries w/validated clinical trials acceptance practices. (The thesis is that each nations regulations are set as equally effective and verified by international agreements/verified periodically)
The message is a powerful one. After many decades of no effective CNS disease treatments available, suddenly the simultaneous release of powerful clinical results will be shown. These not a fluke/PR error, this is all in the WW AVXL plan. This is/will be the opposite of what BIIB did. The FDA will not need to run and hide. We will show simultaneous reports from around the world of efficacy unlike anything ever seen. I understand I am jumping ahead a bit here but, that is what will happen when all these doots get connected.
WHAT A GREAT CONCEPT/PLAN/STRATEGY. BRILLIANT.
.WW-(A very powerful WW clinical messge will be sent)
Locations
54 study locations
Australia, New South Wales
Central Coast Neurosciences Research
Central Coast, New South Wales, Australia
Hornsby (Northern Sydney Health)
Hornsby, New South Wales, Australia
KaRa MINDS
Macquarie Park, New South Wales, Australia
St Vincent Hospital Sydney
Sydney, New South Wales, Australia
University of Sydney
Sydney, New South Wales, Australia
Australia, Quennsland
Gold Coast Memory Disorders Clinic
Southport, Quennsland, Australia
Australia, South Australia
The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH)
Adelaide, South Australia, Australia
Australia, Victoria
Penninsula Therapeutic and Research Group
Frankston, Victoria, Australia
Geelong Private Medical Centre
Geelong, Victoria, Australia
Delmont Private Hospital
Glen Iris, Victoria, Australia
Hammond Care
Malvern, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Austin Health
Melbourne, Victoria, Australia
Monash Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia
Royal Melbourne Hospital (RMH)
Parkville, Victoria, Australia
Australia, Western Australia
McCusker
Nedlands, Western Australia, Australia
Canada, Alberta
Healthy Brain Aging Labs Uni of Calgary
Calgary, Alberta, Canada
Canada, British Columbia
University of British Columbia Hospital
Vancouver, British Columbia, Canada
Vancouver Island Health Authority
Victoria, British Columbia, Canada
Canada, Nova Scotia
True North Clinical Research
Halifax, Nova Scotia, Canada
True North Clinical Research
Kentville, Nova Scotia, Canada
Canada, Ontario
Parkwood Institute
London, Ontario, Canada
Bruyere Continuing Care
Ottawa, Ontario, Canada
Kawartha Centre
Peterborough, Ontario, Canada
Bay Crest Health Sciences
Toronto, Ontario, Canada
Toronto Memory Program
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
Germany
University of Ulm, Memory Clinic
Ulm, Baden-Wuerttemberg, Germany
Bayreuth Clinic, Hohe Warte Hospital
Bayreuth, Bavaria, Germany
Technical University of Munich, School of Medicine
München, Bavaria, Germany
Central Institute of Mental Health
Mannheim, Hessen, Germany
Goettingen University Medicine, Clinic for Psychiatry and Psychotherapy
Göttingen, Lower Saxony, Germany
University Hospital, Bonn
Bonn, North Rhine-Westphalia, Germany
Clinic for Psychiatry and Psychotherapy
Mainz, Rheinland-Pfalz, Germany
Charite University Medicine
Berlin, Germany
Netherlands
Brain Research Center
Amsterdam, Netherlands
Brain Research Center
Den Bosch, Netherlands
Brain Research Center
Zwolle, Netherlands
United Kingdom
MAC Clinical Research
Teesside, County Teesside, United Kingdom
University of Edinburgh
Edinburgh, Scotland, United Kingdom
Glasgow Memory Clinic
Glasgow, Scotland, United Kingdom
Cognition Health
Guildford, Surrey, United Kingdom
MAC Clinical Research
Barnsley, United Kingdom
Cognition Health
Birmingham, United Kingdom
MAC Clinical Research
Blackpool, United Kingdom
MAC Clinical Research
Cannock, United Kingdom
MAC Clinical Research
Leeds, United Kingdom
MAC Clinical Research
Liverpool, United Kingdom
Cognition Health
London, United Kingdom
Imperial College
London, United Kingdom
King's College
London, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Cognition Health
Plymouth, United Kingdom
Southern Health NHS Foundation Trust
Southampton, United Kingdom
Sponsors and Collaborators
Anavex Life Sciences Corp.
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Anavex Canada Ltd.
Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)
Actual Study Start Date :
July 3, 2018
Estimated Primary Completion Date :
May 30, 2022
Estimated Study Completion Date :
June 30, 2022
https://clinicaltrials.gov/ct2/show/NCT03790709
****************************
Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Actual Study Start Date :
October 10, 2019
Estimated Primary Completion Date :
April 2022
Estimated Study Completion Date :
June 2022
https://clinicaltrials.gov/ct2/show/NCT04575259
